

Bictegravir

Catalog No: tcsc0014685



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1611493-60-7

Formula:

$C_{21}H_{18}F_3N_3O_5$

Pathway:

Metabolic Enzyme/Protease;Anti-infection

Target:

HIV Integrase;HIV

Purity / Grade:

>98%

Solubility:

DMSO : 83.3 mg/mL (185.37 mM; Need ultrasonic and warming)

Alternative Names:

GS-9883

Observed Molecular Weight:


449.38

Product Description

Bictegravir is a novel, potent inhibitor of **HIV-1 integrase** with an **IC₅₀** of 7.5 nM.

IC50 & Target: IC50: 7.5 nM (HIV-1 integrase)^[1]

In Vitro: Bictegravir (BIC) inhibits the strand transfer activity with an IC₅₀ of 7.5 ± 0.3 nM. Relative to its inhibition of strand transfer activity, Bictegravir is a much weaker inhibitor of 3'-processing activity of HIV-1 IN, with an IC₅₀ of 241 ± 51 nM. Bictegravir enhances the accumulation of 2-LTR circles ~5-fold relative to the mock-treated control and reduces the amount of authentic integration products in infected cells by 100-fold. Bictegravir potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC₅₀s of 1.5 and 2.4 nM, respectively. Bictegravir exhibits potent antiviral effects in both primary CD4⁺ T lymphocytes and monocyte-derived macrophages, with EC₅₀s of 1.5 ± 0.3 nM and 6.6 ± 4.1 nM, respectively, which are comparable to values obtained in T-cell lines^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!